FibroBiologics secures up to $25M standby equity facility with Yorkville; first $5M funded

FibroBiologics, Inc.

Yorkville advanced $5M initial tranche of $15M pre-paid convertible notes; two additional $5M tranches subject to conditions.
Conversion price lower of $2.41/share or 94% of 5-day VWAP; 0% interest (18% upon default), matures Dec 2025.
Additional $10M common stock purchase commitment available under SEPA over two years, subject to Yorkville's consent.
CEO states proceeds will fund first-in-human diabetic foot ulcer trial and psoriasis IND-enabling studies.
Shareholder approval required for issuances exceeding 19.99% of outstanding shares (Exchange Cap).

item 1.01 item 2.03 item 3.02 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.